Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer
Open Access
Abstract
We treated highly metabolically adaptable (SUM149-MA) triple-negative inflammatory breast cancer cells and their control parental SUM149-Luc cell line with JQ1 for long periods to determine its efficacy at inhibiting therapy-resistant cells. After 20 days of treatment with 1–2 µM of JQ1, which killed majority of cells in the parental cell line, a large number of SUM149-MA cells survived, consistent with their pan-resistant nature. Interestingly, though, the JQ1 treatment sensitized resistant cancer cells in both the SUM149-MA and SUM149-Luc cell lines to subsequent treatment with doxorubicin and paclitaxel. To measure JQ1-mediated sensitization of resistant cancer cells, we first eradicated approximately 99% of relatively chemotherapy-sensitive cancer cells in culture dishes by long treatments with doxorubicin or paclitaxel, and then analyzed the remaining resistant cells for survival and growth into colonies. In addition, combination, rather than sequential, treatment with JQ1 and doxorubicin was also effective in overcoming resistance. Notably, Western blotting showed that JQ1-treated cancer cells had significantly lower levels of PD-L1 protein than did untreated cells, indicating that JQ1 treatment may reduce tumor-mediated immune suppression and improve the response to immunotherapy targeting PD-L1. Finally, JQ1 treatment with a low 62.5 nM dose sensitized another resistant cell line, FC-IBC02-MA, to treatment with doxorubicin and paclitaxel.Keywords
All Related Versions
Funding Information
- U.S. Army Medical Command (DAMD17-03-1-0669 W81XWH-09-1-0590, P30CA016672)
- State of Texas Rare and Aggressive Breast Cancer Research Program (DAMD17-03-1-0669 W81XWH-09-1-0590, P30CA016672)
- Breast Cancer Metastasis Research Program at MD Anderson (DAMD17-03-1-0669 W81XWH-09-1-0590, P30CA016672)
- NIH/NCI (DAMD17-03-1-0669 W81XWH-09-1-0590, P30CA016672)
This publication has 33 references indexed in Scilit:
- Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung CancerClinical Cancer Research, 2013
- Inflammatory breast cancer (IBC): clues for targeted therapiesBreast Cancer Research and Treatment, 2013
- Inhibition of BET Bromodomain Targets Genetically Diverse GlioblastomaClinical Cancer Research, 2013
- Selection of Metastatic Breast Cancer Cells Based on Adaptability of Their Metabolic StatePLOS ONE, 2012
- Selective inhibition of BET bromodomainsNature, 2010
- Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancerClinical & Experimental Metastasis, 2010
- COX-2 involvement in breast cancer metastasis to boneOncogene, 2007
- A Pooled Analysis of Bone Marrow Micrometastasis in Breast CancerNew England Journal of Medicine, 2005
- Evidence for the Clonal Origin of Spontaneous MetastasesScience, 1982
- The Clonal Evolution of Tumor Cell PopulationsScience, 1976